PMID- 27412942
OWN - NLM
STAT- MEDLINE
DCOM- 20170113
LR  - 20201209
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 32
IP  - 8
DP  - 2016 Aug
TI  - [Xinfeng capsule improves hypercoagulative state by inhibiting miR-155/NF-kappaB 
      signaling pathway in patients with active ankylosing spondylitis].
PG  - 1094-8
AB  - Objective To observe the effect of Xinfeng capsule (XFC) on miR-155, nuclear 
      factor kappa B (NF-kappaB) signal pathway, and indexes related to hypercoagulative 
      state in patients with active ankylosing spondylitis (AS), and investigate the 
      possible mechanism. Methods Fifty-six cases in active AS were randomly divided 
      into XFC group and sulfasalazine (SASP) group. All cases in the XFC group took 
      three capsules three times daily for twelve consecutive weeks. The ones in the 
      SASP group took four tablets two times daily for twelve consecutive weeks. The 
      expression of miR-155 was detected by real-time PCR. The mRNA expressions of 
      nuclear factor kappaB activator 1(Act1), NF-kappaB inhibitor-alpha (IkappaBalpha), inhibitor of 
      kappa-B kinase beta (IKKbeta), NF-kappaB p65, and NF-kappaB p50 were tested by reverse 
      transcription PCR (RT-PCR). Meanwhile, the protein expressions of NF-kappaB P65 and 
      NF-kappaB P50 were determined by Western blotting. Tumor necrosis factor-alpha 
      (TNF-alpha), interleukin (IL)-4, IL-10, IL-17, thromboxane B2 (TXB2), 
      6-ketone-prostaglandin F1 (6-keto-PGF1), platelet granular membrane protein 140 
      (GMP140), platelet activation factor (PAF), and plasminogen activator inhibitor-2 
      (PAI-2) were determined by ELISA. Clinical efficacy was evaluated in the two 
      groups. Results Compared with the SASP group, 50% Bath ankylosing spondylitis 
      disease activity index (BASDAI50) was significantly higher in the XFC group. 
      Compared with the SASP group after treatment, platelet (PLT), fibrinogen (FBG) 
      and D-D dimer (D-D), TXB2, GMP140, PAF, PAI-2, IL-17, erythrocyte sedimentation 
      rate (ESR), C-reactive protein (CRP), visual analog scale (VAS), BASDAI, BASFI, 
      and BAS-G were reduced more obviously in the XFC group after treatment; 
      meanwhile, 6-keto-PGF1, IL-4, and IL-10 significantly increased. Compared with 
      the SASP group after treatment, the expressions of IKKbeta mRNA, IkappaBalpha mRNA, NF-kappaB 
      p65 mRNA, NF-kappaB p50 mRNA, NF-kappaB P65 protein, NF-kappaB P50 protein, and miR-155 were 
      lower in the XFC group after treatment. Conclusion XFC could effectively improve 
      hypercoagulative state in active AS patients. The potential mechanism may be 
      associated with the inhibition of miR-155 and NF-kappaB signal pathway.
FAU - Fang, Li
AU  - Fang L
AD  - Anhui university of Chinese Medicine, Hefei 230038, China.
FAU - Liu, Jian
AU  - Liu J
AD  - Department of Rheumatism, First Affiliated Hospital, Anhui University of Chinese 
      Medicine, Hefei 230031, China.*Corresponding author, E-mail: liujianahzy@126.com.
FAU - Wan, Lei
AU  - Wan L
AD  - Department of Rheumatism, First Affiliated Hospital, Anhui University of Chinese 
      Medicine, Hefei 230031, China.
FAU - Zhu, Fubing
AU  - Zhu F
AD  - Anhui university of Chinese Medicine, Hefei 230038, China.
FAU - Tan, Bing
AU  - Tan B
AD  - Anhui university of Chinese Medicine, Hefei 230038, China.
FAU - Zhang, Pingheng
AU  - Zhang P
AD  - Anhui university of Chinese Medicine, Hefei 230038, China.
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Capsules)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (MIRN155 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - 0 (NF-kappa B p50 Subunit)
RN  - 0 (TRAF3IP2 protein, human)
RN  - 0 (Transcription Factor RelA)
RN  - 0 (Tumor Necrosis Factor Receptor-Associated Peptides and Proteins)
RN  - 0 (xinfeng)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing
MH  - Adult
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests
MH  - Blotting, Western
MH  - Capsules
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - NF-kappa B/*genetics/metabolism
MH  - NF-kappa B p50 Subunit/genetics/metabolism
MH  - Phytotherapy/methods
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/*drug effects/genetics
MH  - Spondylitis, Ankylosing/blood/*drug therapy/genetics
MH  - Transcription Factor RelA/genetics/metabolism
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor Receptor-Associated Peptides and 
      Proteins/genetics/metabolism
MH  - Young Adult
EDAT- 2016/07/15 06:00
MHDA- 2017/01/14 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/01/14 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Aug;32(8):1094-8.